Amgen CEO Bob Bradway stood in Holly Springs last Friday and thanked public officials for making the brand new $500 million drug manufacturing plant behind him a reality.

Amgen and Genentech generally came up around the same time. When Genentech went the buyout route with a sale to Swiss drugmaker Roche in 2009, speculation about Amgen’s future followed.

Amgen and its CEO Robert Bradway were sued for failing to disclose billions of dollars in back taxes and penalties owed to the IRS. By Alexandra Tremayne-Pengelly • 03/15/23 2:25pm.

Amgen said its experimental weight loss injection helped patients lose up to 20% ... which we will explore in phase three development," Amgen CEO Robert Bradway said on a call with investors ...

Amgen CEO Robert Bradway scored a 5.8% increase in overall compensation last year mostly thanks to the company’s acquisition of Horizon Therapeutics. For 2023, Amgen granted Bradway $22.6 ...

Amgen CEO Bradway credits President Donald Trump for 2017 Tax Cuts and Jobs Act reform for Holly Springs, North Carolina, plant opening.

Today we start with some breaking newss: Novo Nordisk’s CEO is stepping down. We also discuss a new, tailored CRISPR treatment for an infant with a deadly disease, how Amgen owes Regeneron more ...

Amgen stock soared as much as 16% on Friday after it reported first-quarter earnings. The company talked up its experimental GLP-1 weight-loss drug, MariTide. The new weight loss drug could be ...

Like his pharma and biotech leadership peers, Amgen CEO Robert A. Bradway took home a multimillion payday in 2022, pocketing $21.4 million last year. Though slightly down from the $21.7 total ...

Amgen Inc. announced on Monday that it will acquire Horizon Therapeutics for $26 billion to further grow the company’s medical legacy. Horizon's best-selling drug is Tepezza.

Amgen said its experimental weight loss injection helped patients lose up to 20% of their weight on average after a year, with no plateau, in a critical mid-stage trial.